I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AAIC 2026

We will be contributing to topics related to
-
06:30 AM
Duration 60mins London, United Kingdom
Expanding clinical trial access to underrepresented populations in the US: Findings from the Alzheimer’s disease pre-screener study
Irma Kurniawan, Tamiko MaGee-Rodgers, Luisa Guglielmini, Justin Ford, Mia Chester,Theo Christofides, Enrique Gaspar, Kelly Coultes, Christopher Lane, Lisa Squassante, Nicola Maiorano, Julian Tillmann, Rosanna Tortelli, Ruth Croney
06:30 AM
Duration 60mins London, United Kingdom
Investigating the Role of the NLRP3 Inflammasome in the Pathogenesis of Alzheimer’s Disease
Gennaro Pagano, Eva Mracsko, Eric Prinssen, Bastian Zinnhardt, Venissa Machado, Senthilvelrajan Kaniyappan, Stanislaw Adaszewski, Livia Takacs, Luka Kulic, Nicoletta Milani Muelhardt, Geoffrey A. Kerchner
01:00 PM
Duration 90mins London, United Kingdom, Room S8
Long-term safety and amyloid removal with trontinemab: interim data from the open-label extension of the Phase Ib/IIa Brainshuttle™ AD study
Luka Kulic
Duration 90mins London, United Kingdom, Room S8
PrevenTRON: Rationale and design of a Phase III trial of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline
Janice Smith
Duration 90mins London, United Kingdom, Room S8
Simulation of amyloid clearance in Phase III studies with trontinemab in early symptomatic Alzheimer’s disease
Joao Abrantes
Duration 90mins London, United Kingdom, Room S8
Interim long-term biomarker results from the trontinemab open-label extension of the Phase Ib/IIa Brainshuttle™ AD study
Gregory Klein
Duration 90mins London, United Kingdom, Room S8
Evidence supporting preclinical AD as an optimal stage for intervention with trontinemab
Reisa Sperling
06:30 AM
Duration 60mins London, United Kingdom
Mental health conditions in spouses of people lliving with Alzheimer’s disease: a longitudinal US claims data analysis
Lars Kamber, Michelle Johnson, Valerie Crowell, Soeren Mattke, Richard Houghton
Duration 60mins London, United Kingdom
A Low-Burden Cognitive Prescreening Protocol for Enhanced Diversity and Recruitment in Roche’s Alzheimer’s Disease Clinical Trials
Irma Kurniawan, Enrique Gaspar, Ruth Croney, Nicola Maiorano, Kelly Coultes, Christopher Lane, Lisa Squassante, Julian Tillmann, Rosanna Tortelli
Coming soon